KBC Group’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$33.9M Buy
423,024
+51,266
+14% +$4.23M 0.09% 205
2025
Q4
$31.7M Sell
371,758
-107,030
-22% -$8.78M 0.07% 209
2025
Q3
$37.2M Sell
478,788
-411
-0.1% -$32.1K 0.09% 192
2025
Q2
$37.5M Buy
479,199
+486
+0.1% +$36.2K 0.1% 192
2025
Q1
$34.7M Sell
478,713
-169,129
-26% -$12.1M 0.11% 196
2024
Q4
$48M Sell
647,842
-248,320
-28% -$17.4M 0.13% 152
2024
Q3
$59.1M Buy
896,162
+104,499
+13% +$7.59M 0.18% 111
2024
Q2
$73.1M Buy
791,663
+52,846
+7% +$4.68M 0.22% 89
2024
Q1
$70.6M Sell
738,817
-817,836
-53% -$68.7M 0.22% 99
2023
Q4
$119M Sell
1,556,653
-206,996
-12% -$14.4M 0.42% 50
2023
Q3
$122M Buy
1,763,649
+179,398
+11% +$14.4M 0.5% 39
2023
Q2
$149M Buy
1,584,251
+339,208
+27% +$29.5M 0.61% 33
2023
Q1
$103M Buy
1,245,043
+275,999
+28% +$21.7M 0.44% 50
2022
Q4
$72.3M Sell
969,044
-155,336
-14% -$12M 0.35% 64
2022
Q3
$92.9M Buy
1,124,380
+102,216
+10% +$9.84M 0.48% 46
2022
Q2
$97.2M Buy
1,022,164
+358,045
+54% +$37.1M 0.48% 47
2022
Q1
$78.2M Sell
664,119
-366,482
-36% -$41.1M 0.31% 84
2021
Q4
$134M Sell
1,030,601
-204,989
-17% -$23.9M 0.44% 53
2021
Q3
$140M Sell
1,235,590
-1,060,220
-46% -$121M 0.51% 41
2021
Q2
$238M Sell
2,295,810
-39,800
-2% -$3.75M 0.43% 54
2021
Q1
$195M Buy
2,335,610
+167,114
+8% +$14.1M 0.4% 57
2020
Q4
$1.08B Buy
2,168,496
+261,922
+14% +$21.7M 0.46% 48
2020
Q3
$152M Sell
1,906,574
-14,454
-0.8% -$1.13M 0.45% 48
2020
Q2
$133M Buy
1,921,028
+1,007,711
+110% +$71.6M 0.44% 42
2020
Q1
$57.4M Buy
913,317
+354,891
+64% +$25.6M 0.48% 39
2019
Q4
$43.4M Buy
558,426
+37,353
+7% +$2.92M 0.27% 85
2019
Q3
$38.2M Buy
521,073
+14,535
+3% +$1.02M 0.28% 79
2019
Q2
$31.2M Buy
506,538
+93,198
+23% +$5.64M 0.24% 99
2019
Q1
$26.4M Sell
413,340
-117,273
-22% -$6.69M 0.22% 109
2018
Q4
$27.1M Sell
530,613
-348,933
-40% -$17.7M 0.3% 77
2018
Q3
$51M Buy
879,546
+210,054
+31% +$10.3M 0.39% 58
2018
Q2
$32.5M Buy
669,492
+279,318
+72% +$13M 0.28% 86
2018
Q1
$18.1M Buy
390,174
+40,455
+12% +$1.76M 0.17% 159
2017
Q4
$13.1M Sell
349,719
-1,116
-0.3% -$41K 0.11% 225
2017
Q3
$12.8M Buy
350,835
+56,226
+19% +$2.14M 0.12% 212
2017
Q2
$11.6M Buy
294,609
+135,318
+85% +$4.94M 0.11% 219
2017
Q1
$5M Sell
159,291
-118,092
-43% -$3.7M 0.05% 403
2016
Q4
$8.66M Buy
277,383
+139,719
+101% +$4.53M 0.09% 282
2016
Q3
$5.53M Buy
137,664
+11,898
+9% +$448K 0.07% 321
2016
Q2
$4.18M Sell
125,766
-72,966
-37% -$2.5M 0.06% 349
2016
Q1
$5.84M Sell
198,732
-194,061
-49% -$5.35M 0.1% 258
2015
Q4
$10.3M Buy
392,793
+185,979
+90% +$4.83M 0.19% 147
2015
Q3
$4.9M Sell
206,814
-712,098
-77% -$17.2M 0.1% 251
2015
Q2
$21.8M Buy
918,912
+143,478
+19% +$3.24M 0.28% 97
2015
Q1
$18.4M Buy
775,434
+273,972
+55% +$6.15M 0.24% 115
2014
Q4
$10.6M Sell
501,462
-164,952
-25% -$3.31M 0.13% 190
2014
Q3
$11.3M Buy
666,414
+201,180
+43% +$3.18M 0.4% 43
2014
Q2
$6.66M Buy
465,234
+351,528
+309% +$4.77M 0.08% 323
2014
Q1
$1.41M Sell
113,706
-155,646
-58% -$1.8M 0.02% 574
2013
Q4
$2.95M Buy
269,352
+41,778
+18% +$471K 0.04% 415
2013
Q3
$2.64M Buy
227,574
+123,342
+118% +$1.44M 0.04% 439
2013
Q2
$1.17M Buy
+104,232
New +$1.23M 0.02% 640

Other funds holding EW

KBC Group's EW Position: Q1 2026 in Review

KBC Group increased its Edwards Lifesciences (EW) stake by 14% in Q1 2026, buying an estimated $4.23M and bringing the position to 423,024 shares worth $33.9M. The position accounts for 0.09% of the portfolio, ranked #205.

KBC Group first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.08B in Q4 2020. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • KBC Group held 423,024 shares of Edwards Lifesciences worth $33.9M as of Q1 2026.
  • KBC Group bought 51,266 Edwards Lifesciences shares in Q1 2026, an estimated $4.23M.
  • Edwards Lifesciences made up 0.09% of KBC Group's portfolio in Q1 2026, its #205 holding.
  • KBC Group first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • KBC Group's Edwards Lifesciences position peaked at $1.08B in Q4 2020.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.